🎙 The eye warning the FDA added to Ozempic | The Receipts - Dataspheres AI

The eye warning the FDA added to Ozempic (5 min), with captions The story On Monday, November 9, the Food and Drug Administration published a drug safety c...

The eye warning the FDA added to Ozempic (5 min), with captions The story On Monday, November 9, the Food and Drug Administration published a drug safety communication ordering a new warning onto the labels of every GLP-1 drug sold in the United States. The warning covers a rare eye condition that can cause sudden, painless vision loss in one eye, including permanent loss. It goes in the warnings and precautions section of the label. No product has been withdrawn and no patient has been told to stop taking these medicines. The condition is non-arteritic anterior ischemic optic neuropathy, known as NAION, which the FDA describes as rare and caused by a drop in blood supply to the front of the optic nerve. Twelve products covering seven active ingredients are named, from semaglutide (Ozempic, Rybelsus and Wegovy) and tirzepatide (Mounjaro and Zepbound) to liraglutide, exenatide, dulaglutide, lixisenatide and orforglipron. The order is class-wide, reaching from the newest drugs down to the oldest GLP-1 on the market. The decision rests on a meta-analysis of 126 randomised trials covering 134,253 patients and 288,879 person-years of treatment. Those trials recorded 6.4 events per 100,000 person-years on a GLP-1 drug against 3.8 on a comparator — ten cases against five in raw counts, with none among people taking other glucose-lowering drugs. The FDA also cited published observational studies, which it says consistently point the same way, and its own Sentinel real-world database covering 2019 to 2024, where a comparison against one class of diabetes drugs was statistically significant and against another was not. Europe moved first. On June 6, 2025, the European Medicines Agency's safety committee concluded that the condition is a very rare side effect of semaglutide, potentially affecting up to one in 10,000 people, at about twice the risk of people not taking the medicine — roughly one extra case per 10,000 person-years of treatment. Novo Nordisk, which makes Ozempic, Wegovy and Rybelsus, told Reuters that the data do not establish a cause-and-effect relationship and said it remains confident in the benefit-risk profile of its medicines. Eli Lilly, which makes Mounjaro and Zepbound, said the communication applies to all medicines with GLP-1 activity and pointed to no finding specific to its own. The warning reaches a large population. KFF asked a nationally representative sample of 1,350 American adults between October 27 and November 2, 2025, and 12 per cent said they were taking a GLP-1 drug at that moment, while 18 per cent said they had taken one at some point. The FDA's advice to patients is specific: sudden, painless loss of vision in one eye means contacting a health care professional right away, as does a missing patch of vision, distorted colour or a drop in central sharpness. Prescribers are told to refer those patients promptly to an ophthalmologist. Nobody is told to stop taking the drug on their own. Highlights Highlight In pictures Listen The episode as audio